What are the key leadership changes announced?

John H. Hammergren is retiring as CEO and Chairman on March 31, 2019. Brian S. Tyler will succeed him as CEO on April 1, 2019, and Edward A. Mueller will become Chairman of the Board on April 1, 2019.

What is the new strategic growth initiative about?

McKesson is initiating a multi-year strategic growth initiative aimed at improving patient care delivery through innovative solutions. Key focus areas include expanded supply chain and commercialization services for manufacturers, enhanced solutions for the specialty pharmaceutical market, and new offerings for retail pharmacies.

Why were incentive awards granted to executives?

The awards were granted as part of the new strategic growth initiative to enhance the company's competitive position and retain key executives with critical skills. The goal is to ensure strong leadership continuity and execution of the long-term strategy.

How are the executive incentive awards structured?

Each award is valued at $5 million and is split equally between performance stock units (PSUs) and restricted stock units (RSUs). The PSUs are tied to achieving incremental Adjusted Operating Profit (AOP) targets over a three-year period (FY2019-FY2021) and require positive absolute total shareholder return (TSR) for payouts above target. RSUs vest fully on the third anniversary of the grant date (November 2021).

MCK 8-K: Leadership Changes

Summary

McKesson Corporation (MCK) has filed an 8-K report detailing significant leadership changes and executive compensation adjustments tied to a new strategic growth initiative. The company announced the retirement of CEO and Chairman John H. Hammergren, effective March 31, 2019, with President and COO Brian S. Tyler slated to succeed him as CEO, and Lead Independent Director Edward A. Mueller becoming Chairman. This transition occurs as McKesson embarks on a multi-year growth strategy focused on improving patient care delivery, expanding supply chain services, and enhancing its role in the specialty pharmaceutical and retail pharmacy markets. In conjunction with this strategic initiative and to ensure executive retention during this period of change, the Compensation Committee approved one-time incentive awards for three key executives: Britt Vitalone (CFO), Lori A. Schechter (General Counsel), and Bansi Nagji (Chief Strategy Officer). These awards, valued at $5 million each, consist of performance stock units (PSUs) and restricted stock units (RSUs) designed to align executive compensation with significant financial outperformance and shareholder returns.

Key Highlights

1John H. Hammergren to retire as CEO and Chairman on March 31, 2019.
2Brian S. Tyler, current President and COO, will become CEO effective April 1, 2019.
3Edward A. Mueller, current Lead Independent Director, will assume the role of Chairman of the Board effective April 1, 2019.
4Company is launching a multi-year strategic growth initiative focused on improving patient care delivery, expanding services, and enhancing market position.
5One-time incentive awards totaling $5 million each were granted to CFO Britt Vitalone, General Counsel Lori A. Schechter, and Chief Strategy Officer Bansi Nagji.
6Awards consist of 50% Performance Stock Units (PSUs) and 50% Restricted Stock Units (RSUs), vesting over three to four years.
7PSUs are tied to achieving incremental Adjusted Operating Profit (AOP) goals above long-range plan targets and require positive absolute total shareholder return (TSR) for payouts above target.

MCKESSON CORP 8-K Report, Executive Changes (Nov 9, 2018)

Summary

Key Highlights

Frequently Asked Questions